Nojoto: Largest Storytelling Platform
Download Nojoto

Install App Get upto ₹ 100 Cash

AstraZeneca admits its Covishield vaccine may lead

AstraZeneca admits its Covishield vaccine may lead to rare side effect AstraZeneca has admitted for the first time in court documents that its Covid vaccine can cause rare side effects, marking an about-turn that may open the door for a multi-million pound legal payout AstraZeneca has admitted for the first time in court documents that its Covid-19 vaccine, sold globally under the brand names Covishield and Vaxzevria among others, may lead to a rare side-effect. According to media reports, the admission was made in a legal document submitted to the UK High Court in February. The company stated in the document that a rare side effect known as Thrombosis with Thrombocytopenia Syndrome (TTS) can happen even if there is no vaccination, adding that expert testimony will be required to determine causation in every individual case. It said, “It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known." Developed in collaboration with University of Oxford, AstraZeneca’s vaccine was manufactured in India by Pune-based Serum Institute of India (SII). As many as 1,749,417,978 doses of Covishield vaccine have been administered in India, in what was the world’s largest vaccination programme from January 2021, according to the vaccine dashboard of the government's web portal CoWIN (as of 10:30 pm April 29, 2024). ©SHIRSENDU KARMAKAR #AstraZeneca #Covishield
shirsendukarmaka6666

SHIRSENDU KARMAKAR

New Creator
streak icon518

#AstraZeneca #covishield #Motivational

90 Views